Companies › Tecnoquimicas
1 active drug program in 1 registered trial: 1 Phase 4; Ophthalmology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Preservative-free dorzolamide-timolol-brimonidine combination Carbonic anhydrase inhibitor (dorzolamide), beta-adrenergic antagonist (timolol), and alph | CA2, ADRB1, ADRA2A | Phase 4 | Primary Open-Angle Glaucoma (POAG) | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07690397 | Preservative-free dorzolamide-timolol-brimonidine combination | Phase 4 | Primary Open-Angle Glaucoma (POAG) | Ophthalmology | Jul 2027 |
ARS Pharmaceuticals Acer Therapeutics Upsher-Smith Laboratories Shionogi Incannex Healthcare Actimed Therapeutics EyeD Pharma Guangzhou Novaken Pharm Santen SAS Pharmazz
MeiraGTx Ocular UK Neurotech Pharmaceuticals Innostellar Biotherapeutics jCyte NovaSight
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.